- Home
- KALA vs SRZN Comparison
KALA vs SRZN Comparison
Compare KALA & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- SRZN
- Stock Information
- Founded
- KALA 2009
- SRZN 2015
- Country
- KALA United States
- SRZN United States
- Employees
- KALA N/A
- SRZN N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- KALA Health Care
- SRZN Health Care
- Exchange
- KALA Nasdaq
- SRZN Nasdaq
- Market Cap
- KALA 32.0M
- SRZN 38.1M
- IPO Year
- KALA 2017
- SRZN N/A
- Fundamental
- Price
- KALA $6.48
- SRZN $8.99
- Analyst Decision
- KALA Strong Buy
- SRZN
- Analyst Count
- KALA 2
- SRZN 0
- Target Price
- KALA $15.00
- SRZN N/A
- AVG Volume (30 Days)
- KALA 33.2K
- SRZN 33.9K
- Earning Date
- KALA 11-12-2024
- SRZN 11-06-2024
- Dividend Yield
- KALA N/A
- SRZN N/A
- EPS Growth
- KALA N/A
- SRZN N/A
- EPS
- KALA N/A
- SRZN N/A
- Revenue
- KALA N/A
- SRZN $10,000,000.00
- Revenue This Year
- KALA N/A
- SRZN N/A
- Revenue Next Year
- KALA N/A
- SRZN N/A
- P/E Ratio
- KALA N/A
- SRZN N/A
- Revenue Growth
- KALA N/A
- SRZN N/A
- 52 Week Low
- KALA $4.21
- SRZN $6.00
- 52 Week High
- KALA $10.97
- SRZN $16.19
- Technical
- Relative Strength Index (RSI)
- KALA 49.93
- SRZN 45.92
- Support Level
- KALA $6.00
- SRZN $8.10
- Resistance Level
- KALA $7.85
- SRZN $10.76
- Average True Range (ATR)
- KALA 0.40
- SRZN 1.25
- MACD
- KALA -0.11
- SRZN -0.16
- Stochastic Oscillator
- KALA 29.19
- SRZN 22.90
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).